ORGANIZATION

Regional Formulary Initiatives Underway, Eyes on Cost Control for Branded Drugs with No Gx

January 22, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

As Japan’s generic utilization rate is nearing a plateau, there are emerging initiatives to forge regional drug formularies to curtail costs not only through a switch from long-listed products (LLPs), but also from brand-name medicines with no low-cost copies. A…

To read the full story

Chuikyo Reps Give Kudos to Formulary Initiatives, but Wary on Creating Medical Fees
June 27, 2019
Drug Formulary Initiatives Moving Beyond Hospitals, Generic Makers Prepping for Regional Lists
January 30, 2019

ORGANIZATION

Japanese Drug Makers Step Up Use of ASEAN Reliance Reviews
June 18, 2026
Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
Raise Foreign Price Adjustment Cap for Listed Products in German Cases: FPMAJ
June 15, 2026
FPMAJ Seeks Predictability in Price Maintenance System for Innovative Medicines
June 15, 2026
LLP Extra Patient Charge Influences Generic Adoption at Over 40% of Hospitals: FPMAJ
June 15, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…